tasocitinib

Pfizer's Potential Arthritis Drug Works in Late-Stage Trial

Pfizer shares were down more than 1% Monday afternoon despite the pharmaceutical giant's report Sunday of successful late-stage trial results for an experimental rheumatoid arthritis drug. The study showed tasocitinib reduced pain and inflammation and improved physical function in patients with moderately to severely active RA.